Clinical Trial

Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

Enrolling by Invitation Phase 4
View on ClinicalTrials.gov →
Summary
In postmenopausal women, obesity increases the risk of physical function decline, premature aging, and vascular dysfunction. Semaglutide and tirzepatide are potent obesity medications. The goal is to determine the effect of weight loss induced by the new generation of GLP-1 receptor agonists on physical function, aging biomarkers, and vascular function in postmenopausal women with obesity.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-30.
Trial Details
NCT Number NCT07057310
Lead Sponsor Mayo Clinic
Conditions Obesity, Menopause
Enrollment 30 participants
Start Date 2025-05-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-20